A Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects

NCT04793204 | Completed Phase 1

• 1 other identifier: 2693-CL-0030
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of fezolinetant after single-dose and multiple dose administration in healthy Chinese female participants.

Conditions

Healthy Volunteers

Keywords

Fezolinetant; Pharmacokinetics; ESN364; Healthy Volunteer

Outcome Measures

Primary Outcomes (33)

• Number of participants with Adverse Events (AEs)

  Adverse events (AEs) will be coded using medical dictionary for regulatory activities (MedDRA). An AE is any untoward medical occurrence in a participant administered a study drug and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medical product whether or not considered related to the medical product. An AE is considered "serious" if, in the view of either the investigator or sponsor, the event: results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires hospitalization or prolongation to hospitalization, or other medically important event.

  Up to day 41

• Number of participants with laboratory value abnormalities and/or adverse events (AEs)

  Number of participants with potentially clinically significant laboratory values.

  Up to day 41

• Number of participants with vital sign abnormalities and/or adverse events (AEs)

  Number of participants with potentially clinically significant vital sign values.

  Up to day 41

• Number of participants with rountine 12 lead electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)

  Number of participants with potentially clinically significant ECG values.

  Up to day 41

• Pharmacokinetics (PK) of fezolinetant in plasma: AUC24

  Area under the concentration-time curve from the time of dosing to 24 hours (AUC24) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 7

• Pharmacokinetics (PK) of fezolinetant in plasma: AUCinf

  AUC from the time of dosing extrapolated to time infinity (AUCinf) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 7

• Pharmacokinetics (PK) of fezolinetant in plasma: AUCinf(%extrap)

  Percentage of extrapolated section of AUCinf (AUCinf(%extrap)) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 7

• Pharmacokinetics (PK) of fezolinetant in plasma: AUClast

  Area under the concentration time curve from the time of dosing to the last measurable concentration (AUClast) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 7

• Pharmacokinetics (PK) of fezolinetant in plasma: Ctrough

  Concentration immediately prior to dosing at multiple dosing (trough concentration) (Ctrough) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of fezolinetant in plasma: AUCtau

  AUC from the time of dosing to the start of the next dosing interval (AUCtau) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of fezolinetant in plasma: CL/F

  Apparent total clearance after extra-vascular dosing (CL/F) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of fezolinetant in plasma: Cmax

  Maximum concentration (Cmax) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of fezolinetant in plasma: PTR

  Peak-trough ratio (PTR) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of fezolinetant in plasma: Rac(AUC)

  Accumulation ratio calculated using AUC (Rac(AUC)) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of fezolinetant in plasma: Rac(Cmax)

  Accumulation ratio calculated using Cmax (Rac(Cmax)) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of fezolinetant in plasma: t1/2

  Terminal elimination half-life (t1/2) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of fezolinetant in plasma: tmax

  Time of the maximum concentration (tmax) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of fezolinetant in plasma: Vz/F

  Apparent volume of distribution during the terminal elimination phase after extra-vascular dosing (Vz/F) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of fezolinetant in plasma: Tlag

  Time-lag (Tlag) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of ES259564 in plasma: AUC24

  Area under the concentration-time curve from the time of dosing to 24 hours (AUC24) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 7

• Pharmacokinetics (PK) of ES259564 in plasma: AUCinf

  Area under the concentration time curve from the time of dosing extrapolated to time infinity (AUCinf) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 7

• Pharmacokinetics (PK) of ES259564 in plasma: AUCinf(%extrap)

  Percentage of extrapolated section of AUCinf (AUCinf(%extrap)) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 7

• Pharmacokinetics (PK) of ES259564 in plasma: AUClast

  Area under the concentration time curve from the time of dosing to the last measurable concentration (AUClast) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 7

• Pharmacokinetics (PK) of ES259564 in plasma: Ctrough

  Concentration immediately prior to dosing at multiple dosing (trough concentration) (Ctrough) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of ES259564 in plasma: AUCtau

  AUC from the time of dosing to the start of the next dosing interval (AUCtau) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of ES259564 in plasma: Cmax

  Maximum concentration (Cmax) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of ES259564 in plasma: PTR

  Peak-trough ratio (PTR) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of ES259564 in plasma: Rac(AUC)

  Accumulation ratio calculated using AUC (Rac(AUC)) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of ES259564 in plasma: Rac(Cmax)

  Accumulation ratio calculated using Cmax (Rac(Cmax)) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of ES259564 in plasma: t1/2

  Terminal elimination half-life (t1/2) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of ES259564 in plasma: tmax

  Time of the maximum concentration (tmax) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of ES259564 in plasma: MPR

  Metabolite to parent ratio (MPR) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

• Pharmacokinetics (PK) of ES259564 in plasma: Tlag

  Time-lag (Tlag) will be recorded from the pharmacokinetic (PK) plasma samples collected.

  Up to day 16

Study Arms (1)

fezolinetant

EXPERIMENTAL

A single oral dose of fezolinetant will be administered with water under fasting conditions on day 1 (low dose), day 4 (medium dose) and day 7 (high dose). From day 10 to day 15, the medium dose of fezolinetant will be administered with water after breakfast once daily. On day 16, the medium dose of fezolinetant will be administered with water under fasting conditions.

Drug: fezolinetant

Interventions

fezolinetant DRUG

oral

Also known as: ESN364

fezolinetant

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subject has a body mass index (BMI) range of \> 19 kg/m\^2 and ≤ 24.9 kg/m\^2.
• Subject has a body weight at screening ≥ 45.0 kg.
• Subject must either:
• Be of nonchildbearing potential: Postmenopausal (defined as at least 1 year without any menses for which there is no other obvious pathological or physiological cause) prior to screening, or documented surgically sterile (e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy)
• Or, if of childbearing potential, agree not to try to become pregnant during the study and for 30 days after the final study drug administration; and have a negative pregnancy test at screening and day -1; and if heterosexually active, agree to consistently use 1 form of effective birth control starting at screening and throughout the study period and for 30 days after the final study drug administration. If male partner has undergone effective surgical sterilization (vasectomy or bilateral orchiectomy), it is not necessary to implement the birth control method.
• Subject must agree not to breastfeed starting at screening and throughout the study period, and for 30 days after the final study drug administration.
• Subject must not donate ova starting at screening and throughout the study period, and for 30 days after the final study drug administration.
• Subject agrees not to participate in another interventional study while participating in the present study, defined as 84 days prior to the screening test until completion of the last study visit.

You may not qualify if:

• Subject has been pregnant within 6 months (including delivery or abortion) or has been breast feeding within 3 months prior to the screening test.
• Subject has had previous exposure with fezolinetant.
• Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to study drug administration.
• Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy.
• Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (noncutaneous) infection within 1 week prior to day -1.
• Subject has any of the liver function tests (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], alkaline phosphatase \[ALP\], gamma-glutamyl transferase \[GGT\] and total bilirubin \[TBL\]) above the upper limit of normal at screening or day -1. In such a case, the assessment is allowed to repeated only once.
• Subject applies to any of the following concerns with regard to tuberculosis.
• History of active tuberculosis
• Significant abnormalities detected in a chest X-ray test at Screening
• Contact with infectious tuberculous patients
• Subject had clinically significant abnormality in their laboratory value at screening test and on day -1.
• Subject who deviated from the following range of vital signs or routine 12-lead electrocardiogram (ECG) results at screening test or day -1. If QT interval corrected by Fridericia method (QTcF) exceeds the limits determined, ECG is allowed to be repeated once; if pulse rate or ear temperature exceeds the limits determined, the measurements of pulse and ear temperature are allowed to be repeated once; if the blood pressure exceed limits determined, the measurement of blood pressure should be repeated once. The final judgment should be based on the retest results.
• Subject has a positive serology test for hepatitis B surface antigen (HBsAg), hepatitis B core (HBc) antibody, hepatitis C virus (HCV) antibodies, human immunodeficiency virus (HIV) antibody, syphilis and hepatitis A virus (HAV) antibodies (immunoglobulin M \[IgM\]) at screening.
• Subject has used any drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, tricyclic antidepressants, phencyclidine, cocaine and opiates) within 3 months prior to day -1. Subject who has a history of drug abuse within 2 years prior to screening test.
• Subject has used any prescribed or nonprescribed drugs (including vitamins, oral contraceptives, hormone replacement therapy \[HRT\], natural and herbal remedies, e.g. St. John's Wort, Chinese medicine such as Heyan Kuntai Capsule) in 3 months prior to study drug administration, except for occasional use of paracetamol (up to 2 g/day) and topical dermatological products, including corticosteroid products.

Sponsors & Collaborators

• Astellas Pharma China, Inc.: lead

Study Sites (1)

Site CN86001

Bei'jing, China

Location

MeSH Terms

Interventions

fezolinetant

Study Officials

• Central Contact

  Astellas Pharma China, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 9, 2021
• First Posted: March 11, 2021
• Study Start: March 24, 2021
• Primary Completion: May 21, 2021
• Study Completion: May 21, 2021
• Last Updated: October 26, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)